---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-23-000144"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:41:36.964339+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q2 FY24 revenue up 5.3% to $7.984B; GAAP EPS $0.68, non-GAAP $1.25; raises FY24 guidance

## Summary
- Revenue $7.984B, +5.3% reported / +5.0% organic; GAAP net income $909M ($0.68 EPS) +113%; non-GAAP EPS $1.25.
- Cardiovascular revenue $2.923B (+5.9%); Neuroscience $2.288B (+4.7%); Medical Surgical $2.142B (+7.0%); Diabetes $610M (+9.7%).
- Raises FY24 organic revenue growth guidance to 4.75% (from 4.5%) and non-GAAP EPS guidance to $5.13–$5.19 (from $5.08–$5.16).
- FDA approvals for Aurora EV-ICD and Symplicity Spyral RDN; CE Marks for Evolut FX TAVR, Simplera CGM, PulseSelect PFA.

## SEC filing metadata
- accession: 0001613103-23-000144
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/0001613103-23-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/mdt-20231121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-23-000144
- JSON: https://secwatch.observer/filing/0001613103-23-000144.json
- Plain text: https://secwatch.observer/filing/0001613103-23-000144.txt

## Key facts
- Earnings Releases
  Medtronic plc reported second quarter of fiscal year 2024 results: revenue Revenue of $8.0 billion. Guidance raised.
  - Period: second quarter of fiscal year 2024
  - Revenue: Revenue of $8.0 billion
  - Guidance: raised
  - Result: reported results
  source text: 2023 – Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights • Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic • GAAP diluted earnings per share (EPS) of $0.68; non-GAAP diluted EPS of $1.25 • Underlying business fundamentals are strong with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1613103/000161310323000144/0001613103-23-000144-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.